Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
58,214,468
-
Shares change
-
-3,319,199
-
Total reported value, excl. options
-
$715,466,637
-
Value change
-
-$45,762,031
-
Put/Call ratio
-
524%
-
Number of buys
-
58
-
Number of sells
-
-55
-
Price
-
$12.29
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2024
140 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58,214,468 shares
.
Largest 10 shareholders include Skorpios Trust (8,906,181 shares), BlackRock, Inc. (5,570,150 shares), Lynx1 Capital Management LP (5,187,191 shares), Redmile Group, LLC (4,713,509 shares), RTW INVESTMENTS, LP (4,652,285 shares), BAKER BROS. ADVISORS LP (4,368,443 shares), MORGAN STANLEY (4,205,307 shares), COWEN AND COMPANY, LLC (3,244,498 shares), VANGUARD GROUP INC (2,759,247 shares), and STATE STREET CORP (1,728,888 shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.